Lutetium Lu 177 vipivotide tetraxetan: first approval
SJ Keam - Molecular diagnosis & therapy, 2022 - Springer
Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177Lu-PSMA-617)
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
Background An updated systematic review and meta‐analysis of relevant studies to
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …
[177Lu] Lu-PSMA-radioligand therapy efficacy outcomes in taxane-naïve versus taxane-treated patients with metastatic castration-resistant prostate cancer: a …
S Satapathy, RK Sahoo, C Bal - Journal of Nuclear Medicine, 2023 - Soc Nuclear Med
Radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA)
inhibitors ([177Lu] Lu-PSMA) is currently approved for patients with metastatic castration …
inhibitors ([177Lu] Lu-PSMA) is currently approved for patients with metastatic castration …
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer-a state of the art review
I Heidegger, C Kesch, A Kretschmer… - Therapeutic …, 2022 - journals.sagepub.com
Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen
(PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer …
(PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer …
Clinical applications of PSMA PET examination in patients with prostate cancer
Simple Summary The prostate specific membrane antigens, abbreviated as PSMAs, are type
II membrane proteins that are highly ex-pressed on the surface of malignant prostate tissue …
II membrane proteins that are highly ex-pressed on the surface of malignant prostate tissue …
177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
R AlSadi, O Bouhali, S Dewji, M Djekidel - The Oncologist, 2022 - academic.oup.com
Background Prostate specific membrane antigen (PSMA) ligand labeled with Lutetium-177
(177Lu) is a promising therapeutic option for metastatic castration-resistant prostate cancer …
(177Lu) is a promising therapeutic option for metastatic castration-resistant prostate cancer …
177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and …
FE von Eyben, K Kairemo, C Paller, MA Hoffmann… - Biomedicines, 2021 - mdpi.com
In this systematic review and network meta-analysis (NMA), we aimed to assess the benefits
and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with …
and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with …
[HTML][HTML] Real-world outcomes and predictive biomarkers for 177Lutetium prostate-specific membrane antigen ligand treatment in metastatic castration-resistant …
M Kafka, A Horninger, G di Santo, I Virgolini… - European Urology …, 2024 - Elsevier
Abstract Background The European Association of Urology guidelines include the lutetium-
177 (177 Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy …
177 (177 Lu) PSMA-617 prostate-specific membrane antigen (PSMA) ligand as a therapy …
Renal and salivary gland functions after three cycles of psma-617 therapy every four weeks in patients with metastatic castration-resistant prostate cancer
T Wollenweber, L Zisser, E Kretschmer-Chott… - Current …, 2021 - mdpi.com
Background:[177Lu] Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and
salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients …
salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients …